Wellgistics Signs LOI for Neuritek Acquisition Amid Financial Distress

What happened

Wellgistics Health has announced a non-binding Letter of Intent to evaluate a potential acquisition of Neuritek Therapeutics for $105 million in an all-stock transaction. This news comes as the company faces severe financial challenges, including a going-concern warning, $24.8 million in debt, and a 47% year-over-year revenue decline in Q3 2025. The proposed deal aims to expand capabilities adjacent to its core pharmacy distribution business, but it does not address the immediate need for refinancing high-cost debt or stabilizing operations. Given Wellgistics' history of dilutive equity issuances and negative cash flow, any stock-based acquisition could further erode shareholder value without providing tangible benefits. Investors should view this as a speculative maneuver that may distract management from urgent survival priorities rather than a credible path to recovery.

Implication

If executed, the all-stock acquisition would likely increase shares outstanding, diluting current equity holders amid an already distressed capital structure with negative operating cash flow. This move could exacerbate management's focus away from critical refinancing of merchant cash advances and Agile term loans, delaying efforts to remove the going-concern warning. The acquisition's success hinges on Neuritek's unproven contributions in neuroscience, adding another layer of execution risk without disclosed revenue or adoption metrics. It aligns with the pattern of narrative pivots noted in the DeepValue report, where technology and expansion stories overshadow core financial woes. Ultimately, investors face heightened dilution and distraction risks, reinforcing the bear case where liquidity tightens and equity holders face further cram-down or wipeout scenarios.

Thesis delta

The acquisition news does not alter the core investment thesis of a distressed equity with high survival risk, as the non-binding LOI lacks immediate financial impact. However, it slightly increases the bear case probability by introducing additional dilution risk if executed and potentially delaying urgent refinancing efforts. Investors should monitor for binding agreements and funding details, but the fundamental concerns around debt, cash flow, and going-concern remain unchanged.